Atazanavir-associated nephrolithiasis : cases from the US food and drug administration's adverse event reporting system

• Published in: AIDS (London) Vol. 21; no. 9; pp. 1215 - 1218
• Main Authors: CHAN-TACK, Kirk M, TRUFFA, Melissa M, STRUBLE, Kimberly A, BIRNKRANT, Debra B
• Format: Journal Article
• Language: English
• Published: Hagerstown, MD Lippincott Williams & Wilkins 31.05.2007
• Subjects: Adenine - analogs & derivatives; Adenine - therapeutic use; Adult; Adverse Drug Reaction Reporting Systems; Antibiotics. Antiinfectious agents. Antiparasitic agents; Antiviral agents; Atazanavir Sulfate; Biological and medical sciences; Drug Therapy, Combination; Female; HIV Infections - drug therapy; HIV Infections - epidemiology; HIV Protease Inhibitors - adverse effects; HIV Protease Inhibitors - therapeutic use; Hospitalization; Human immunodeficiency virus; Human viral diseases; Humans; Infectious diseases; Male; Medical sciences; Middle Aged; Nephrolithiasis - chemically induced; Nephrolithiasis - epidemiology; Nephrolithiasis - surgery; Nephrology. Urinary tract diseases; Oligopeptides - adverse effects; Oligopeptides - therapeutic use; Organophosphonates - therapeutic use; Pharmacology. Drug treatments; Pyridines - adverse effects; Pyridines - therapeutic use; Reverse Transcriptase Inhibitors - therapeutic use; Ritonavir - therapeutic use; Tenofovir; United States - epidemiology; Urinary lithiasis; Viral diseases; Viral diseases of the lymphoid tissue and the blood. Aids; United States; USA; Antiretroviral agent; Endoscopic route; Toxicity; Secondary effect; Antiviral; Ureter; Food and Drug Administration; Kidney disease; Immunopathology; Urinary system disease; Atazanavir; Enzyme; Enzyme inhibitor; Instrumentation therapy; AIDS; Urinary tract disease; Immune deficiency; Urinary stone; Infection; Peptidases; Renal lithiasis; Viral disease; Lithotripsy; Hydrolases; Protease inhibitor
• ISSN: 0269-9370; 1473-5571
• DOI: 10.1097/qad.0b013e32813aee35

The risk of nephrolithiasis associated with atazanavir is not well characterized. The US Food and Drug Administration's Adverse Event Reporting System was searched for reports of nephrolithiasis in HIV-infected patients taking an atazanavir-based regimen. Thirty cases were identified. Many patients required hospitalization for management, including lithotripsy, ureteral stent insertion, or endoscopic stone removal. Some cases of nephrolithiasis resulted in atazanavir discontinuation. Healthcare professionals and patients should be informed that nephrolithiasis is a possible adverse event with atazanavir.